GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that functions as a growth hormone secretagogue by stimulating endogenous growth hormone (GH) release. It acts directly on the pituitary gland's somatotroph cells, promoting GH secretion through receptor activation. Originally developed to explore novel approaches for inducing GH release, GHRP-6 has become a valuable tool in endocrinological research.

The peptide emerged from efforts to identify compounds that mimic the natural stimulatory effects of ghrelin and growth hormone-releasing hormone (GHRH) on the pituitary. Its ability to provoke GH secretion independently of hypothalamic GHRH release distinguishes it mechanistically from other secretagogues. Due to its potent biological activity, GHRP-6 has been extensively studied in vitro and in vivo in various animal models and human research settings.

Within research contexts, GHRP-6 is primarily employed to investigate pituitary GH reserve, characterize GH deficiency syndromes, and evaluate the integrity of the hypothalamic-pituitary axis. Its responsiveness can be influenced by physiological and pathological factors affecting pituitary function, making it a useful pharmacological probe. However, GHRP-6 remains a research-only compound without regulatory approval for clinical use.

Research evaluating GHRP-6 as a diagnostic tool for growth hormone deficiency has demonstrated its capacity to stimulate GH secretion in both pediatric and adult subjects. The 1996 study "Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency" found that while GH responses to GHRP-6 were reduced in GH-deficient individuals, some overlap with normal responses existed. Notably, patients with pituitary stalk transection exhibited near-complete blockade of GH release, highlighting the test’s specificity in identifying severe pituitary disruption. The combined administration of GHRH and GHRP-6 was also explored to improve diagnostic accuracy in adult-onset GH deficiency.

The 2014 publication "N-aminoimidazolidin-2-one peptidomimetics" details the synthesis of conformationally constrained GHRP-6 analogues, underscoring efforts to optimize peptide stability and receptor interaction. These analogues provide valuable insights into the structural requirements for receptor binding and GH secretagogue potency.

More recent investigations, such as the 2024 study "Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms," indicate emerging therapeutic potential beyond GH release. This research highlights GHRP-6’s activation of cellular survival pathways that may mitigate chemotherapy-induced tissue damage, suggesting avenues for future translational studies.

Dosing protocols for GHRP-6 in research settings vary depending on the experimental model and endpoint measured. Intravenous administration is commonly employed to assess acute GH release, with doses adjusted for species, age, and health status. In human studies, doses are typically calibrated to provoke measurable GH secretion without adverse effects, but exact standardized dosing regimens remain to be fully established in the literature.

Animal model investigations often utilize dose ranges designed to elucidate pharmacodynamic properties and receptor interactions, frequently involving multiple administrations to evaluate temporal response patterns. It is important to emphasize that all dosing information pertains solely to research contexts and should not be interpreted as guidance for clinical or human use.